Hosted on MSN1d
FDA Expands Approval of Esketamine for Depression
The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...
The American Journal of Managed Care1d
Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
WUWM19h
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
pharmaphorum1d
FDA approves Janssen’s ketamine-based nasal antidepressant
Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which faces increasing biosimilar competition from its top-selling rheumatoid arthritis drug Remicade.
Medscape1d
Biological Aspects of Postpartum Depression
In comparison with the vast epidemiological literature on postpartum depression (PPD), relatively few studies have examined the biological aspects of the disorder. However, research into the ...
Medscape2d
Later Effects of Psychological Abuse During Pregnancy
Postpartum depression risk increases with psychological abuse, even without physical or sexual violence. Intimate partner violence affects 4% to 8% of pregnant women in the U.S. and is associated ...